Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer
Cancer Chemotherapy and PharmacologyPublished 1 May 1980
Giorgio Bolis, G Bortolozzi, G. Carinelli, Maurizio D’Incalci, F. Gramellini, L. Morasca
Citations26
SJR quartileQ1
SJR score0.97
SNIP0.79
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor response rates and the incidence of side effects was significantly higher in the combination-treatment arm.
Abstract
After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42% and 52%. Median survival times were 13 and 14 months. The incidence of side effects was significantly higher in the combination-treatment arm. No other statistical differences were found.
Keywords
Medicine
PubMedSurgical resection of tumor bulk in the primary treatment of ovarian carcinoma.
817 Citations1975Griffiths Ct
The effect of tumor bulk resection on survival was studied in 102 patients with stages II and III ovarian cancer and the most important factors were the histologic grade of the tumor and the size of the largest residual tumor mass after operation.
New England Journal of MedicineAdvanced Ovarian Adenocarcinoma
322 Citations1978Robert C. Young, Bruce A. Chabner +7 more
PubMedDifferent chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease.
103 Citations1979J H Edmonson, Thomas R. Fleming +6 more
Prognosis was significantly better for older patients despite their generally less favorable performance scores and much of this prognostic superiority appeared to be related to menopausal status and presumably to the depletion of endogenous estrogens in the older patients.
PubMedThe CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).
71 Citations1979Vogl Se, M Berenzweig +3 more
Based on this high level of activity in this poor-risk group, the three drugs were combined with cyclophosphamide in a four-drug regimen (CHAD) for initial therapy suitable for outpatient administration and a prospective randomized trial is planned comparing CHAD to melphalan in previously untreated women with advanced ovarian cancer.
CancerLymphangiography in patients with ovarian epithelial cancer.An evaluation of 289 consecutive cases
51 Citations1977R Musumeci, Alberto Banfi +9 more
From January, 1973, to June, 1976, 226 patients with palpable ovarian masses were evaluated preoperatively by lymphography, showing the highest incidence of metastases was in undifferentiated carcinoma and the lowest, in mesonephroid carcinoma.
Gynecologic OncologyChemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide
47 Citations1974Robert C. Young, George P. Canellos +4 more
Followup indicates that long term disease free survivals are possible in those patients who achieve complete remissions on chemotherapy alone as three of the four patients achieving complete remission in the present study remain free of disease with a median survival in excess of 30 mo.
PubMedMelphalan versus adriamycin in the treatment of advanced carcinoma of the ovary.
45 Citations1975De Palo, De Lena M +4 more
The data indicate that, in patients with carcinoma of the ovary, the therapeutic efficacy of adriamycin is competitive with that of the most effective conventional agents, such as melphalan.
PubMedCombination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial.
43 Citations1976Lloyd Re, Jones Se +3 more
The combination of adriamycin and cyclophosphamide is an effective treatment for carcinoma of the breast, ovary, and endometrium and should be considered for initial chemotherapy in patients with these tumors.
PubMedPrognostic importance of histologic grading in ovarian carcinoma.
36 Citations1975Decker Dg, Malkasian Gd +1 more
The data on ovarian epithelial carcinoma show that within a given stage, regardless of the histologic cell type, the increasingly higher grades have an increasingly poorer prognosis, and chemotherapy should be considered for all tumors beyond grade 1, stage 1a.
Obstetrical & Gynecological SurveyLYMPHANGIOGRAPHY IN PATIENTS WITH OVARIAN EPITHELIAL CANCER
20 Citations1978R Musumeci, Alberto Banfi +9 more
European Journal of Cancer (1965)Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer
8 Citations1976Costantino Mangioni, Giorgio Bolis +2 more
Results demonstrate that this regimen of administration induces remission and prolongation of median survival with a very low level of toxicity and minimal discomfort to the patient.